查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011262

血友病治療市場：依治療分類、給藥方法、最終用戶和通路分類－2026-2032年全球市場預測

Hemophilia Treatment Market by Therapeutic Class, Treatment Mode, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血友病治療市場價值將達到 162.6 億美元，到 2026 年將成長至 172.4 億美元，到 2032 年將達到 254.8 億美元，複合年成長率為 6.62%。

主要市場統計數據
基準年 2025 162.6億美元
預計年份：2026年 172.4億美元
預測年份 2032 254.8億美元
複合年成長率 (%) 6.62%

對血友病治療的當前趨勢、臨床進展、患者期望以及相關人員決策的策略重點，提出了清晰而令人信服的觀點。

在科學突破、醫療服務體系變革以及保險公司和政策制定者日益成長的關注的推動下，血友病治療的現狀正在經歷快速變革時期。近期治療方法的進步重新定義了持續療效和提高生活品質的臨床框架，促使相關人員重新評估臨床路徑和長期照護模式。同時，患者的期望也在改變。患者及其看護者越來越希望治療方法減少出血頻率、簡化給藥流程並最大程度地減少對日常生活的影響。這些期望正在影響臨床醫生、醫療系統和製藥廠商如何優先考慮投資和服務設計。

科學突破、支付方轉變以及分散式照護模式的融合如何重塑整個血友病生態系統的臨床部署和策略重點。

科學創新、支付方行為以及醫療服務體系的現代化共同推動血友病領域的變革。基因編輯和基因替代療法促使人們從長遠角度思考從慢性替代療法轉向更持久的解決方案，促使臨床試驗設計、長期追蹤計畫和生產策略的重新設計。同時，替代療法的改進，包括半衰期更長的產品和替代給藥形式的出現，不斷減輕治療負擔並擴大治療選擇。

不斷變化的定價政策對血友病治療的採購、物流和合約結構，以及由此帶來的治療可及性和商業性穩定性方面的實際影響

到2025年，關稅框架和跨境貿易政策的調整將對所有治療領域的籌資策略、供應鏈韌性和價格談判產生關鍵影響。製造商和經銷商正在重新思考其採購地點和物流系統，以減少可能影響醫療系統和患者承受能力的成本轉移。為此，許多相關人員正在優先考慮供應鏈的透明度和合約的柔軟性，以應對間歇性的成本波動和海關相關的延誤。

將治療方法、治療模式、醫療保健機構和通路聯繫起來的全面細分洞察，揭示了差異化價值創造的機會。

以細分市場為重點的洞察揭示了臨床需求、護理環境和交付管道之間的交集，從而影響療法的引入路徑和服務設計。從治療分類來看，基因療法和替代療法的對比凸顯了二者不同的研發重點。基因療法需要長期安全性監測、專業生產和療效驗證，而替代療法則更注重給藥便利性、供應鏈可靠性和臨床療效的逐步顯現。從治療模式的角度來看，按需治療和預防性治療之間的差異凸顯了不同的病人參與模式和資源利用方式。預防性治療著重於預防出血事件和支援持續用藥依從性計劃，而按需治療則強調快速獲取、急性護理協調和緊急應變能力。

全球主要地區在監管、報銷和醫療保健服務方面的區域差異，如何導致醫療服務獲取動態和商業性模式的差異？

區域趨勢塑造著監管預期、醫療服務規範和支付方框架，這些都直接影響臨床應用和商業策略。在美洲，創新應用通常需要支付方的嚴格審查和複雜的基於結果的合約試點項目。公共和私人支付方都要求提供全面的證據包和真實世界數據來證明高成本干預措施的合理性，而患者權益倡導組織則影響著醫療服務獲取途徑和政策優先事項。各州和省的政策差異進一步增加了複雜性，因此需要製定針對特定區域的參與策略。

在不斷變化的血友病治療領域，關鍵的組織能力、夥伴關係模式和實證策略是區分成功企業的關鍵因素。

企業層面的動態因素區分了那些在臨床上取得成功並獲得永續市場准入的組織與那些面臨重重阻礙的組織。策略領導力、生產規模和強大的實證能力使先進治療方法領域的先驅者和成熟的生物製藥企業能夠應對複雜的監管環境，並確保獲得醫療保險報銷。投資於分散式生產能力、低溫運輸物流以及針對治療中心的專業培訓項目，能夠顯著縮短產品上市時間，並支持治療的連續性。

經營團隊可採取的策略重點，以協調證據產生、供應彈性、支付方參與和以病人為中心的服務，產生持久的影響。

行業領導者應優先考慮一系列事項，使臨床創新與支付方的期望、業務永續營運和以患者為中心的設計保持一致。首先，將建立可靠的真實世界數據 (RWE) 納入研發計劃，以預測支付方的需求並支援基於結果的合約。將註冊登記、遠端監測和患者報告結果 (PRO) 整合到核准後計畫中，有助於機構展示持續的臨床效益並驗證其價值提案。其次，投資於供應鏈的柔軟性和本地物流，以減少關稅相關的干擾，並確保患者能夠不間斷地獲得治療。近岸外包、供應商多元化以及與經銷商簽訂緊急協議有助於維持業務連續性。

透明的混合方法研究設計，結合對專家的初步訪談和系統的二次分析，提供了反映相關人員知識的可重複見解。

本研究方法結合了結構化的原始研究和系統的二手資料分析，以得出平衡的觀點和可靠的結論。原始研究包括對臨床專業人員、支付者、供應鏈專家和患者權益倡導團體代表進行深入訪談，以了解實際情況、報銷考量和實際經驗。這些對話促成了假設驅動型研究的構建，並進行了有針對性的後續研究來檢驗新出現的主題。第二手資料的回顧涵蓋了同行評審文獻、監管指南、臨床試驗報告和公共文件，以支持在當前科學和監管背景下的解釋。

將創新與患者獲得治療聯繫起來的關鍵因素是相關人員的合作、證據的一致性以及強調實際靈活性的簡潔整合。

血友病治療領域正處於十字路口，科學進步、支付方審查和營運需求在此交會。持續的治療創新有望減輕治療負擔並改善患者預後，但要實現這一目標，需要製定以循證醫學為基礎的策略、建立健全的供應鏈以及精心協調的市場參與。積極將臨床開發與支付方要求相結合、投資於患者支援和監測基礎設施、並根據當地情況調整分銷策略的相關人員，將更有能力將創新轉化為可及的醫療保健服務。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 血友病治療市場（依治療方法分類）

  • 基因治療
  • 替代療法

第9章：血友病治療市場（依治療模式分類）

  • 一經請求
  • 預防性治療

第10章 血友病治療市場：依最終用戶分類

  • 家庭醫療保健
  • 醫院
  • 專科診所

第11章 血友病治療市場：依通路分類

  • 離線
  • 線上

第12章 血友病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 血友病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 血友病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國血友病治療市場

第16章：中國血友病治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alnylam Pharmaceuticals, Inc.
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Centessa Pharmaceuticals plc
  • CSL Behring LLC
  • Expression Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • Freeline Therapeutics Holdings plc
  • GC Biopharma Corp.
  • Grifols, SA
  • Kedrion Biopharma Inc.
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Spark Therapeutics, Inc.
  • Swedish Orphan Biovitrum AB（publ）
  • Takeda Pharmaceutical Company Limited
  • uniQure NV
Product Code: MRR-4316E4E894CE

The Hemophilia Treatment Market was valued at USD 16.26 billion in 2025 and is projected to grow to USD 17.24 billion in 2026, with a CAGR of 6.62%, reaching USD 25.48 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.26 billion
Estimated Year [2026] USD 17.24 billion
Forecast Year [2032] USD 25.48 billion
CAGR (%) 6.62%

A clear and compelling orientation to current hemophilia care dynamics, clinical advances, patient expectations, and the strategic priorities shaping stakeholder decisions

The hemophilia treatment landscape is undergoing a rapid period of evolution driven by scientific breakthroughs, shifts in care delivery, and heightened attention from payers and policymakers. Recent therapeutic innovations have reframed clinical conversations around durable benefit and quality-of-life improvements, prompting stakeholders to reassess clinical pathways and long-term care models. At the same time, patient expectations are changing: individuals and caregivers increasingly seek treatments that reduce bleeding frequency, simplify administration, and minimize lifestyle disruption. These expectations are influencing how clinicians, health systems, and manufacturers prioritize investment and service design.

Concurrently, regulatory authorities have adjusted pathways to account for novel modalities, shaping evidence-generation strategies and post-approval monitoring plans. Payers have likewise intensified scrutiny on comparative effectiveness and total cost of care, which encourages manufacturers to align launch strategies with value demonstration and outcomes-based contracting. In parallel, advances in diagnostics and digital health solutions are enhancing monitoring capabilities and enabling more proactive management. Taken together, these dynamics create both opportunity and complexity for developers, providers, and policy-makers seeking to deliver sustainable, patient-centric care.

How converging scientific breakthroughs, payer evolution, and decentralized care models are reshaping clinical adoption and strategic priorities across the hemophilia ecosystem

Transformative shifts in the hemophilia space are emerging from confluence of scientific innovation, payer behavior, and care delivery modernization. Gene-editing and gene-replacement approaches are prompting long-range thinking about a potential shift from chronic replacement regimens to more durable solutions, which in turn is reshaping clinical trial design, long-term follow-up plans, and manufacturing strategies. At the same time, improvements in replacement therapies, including extended half-life products and alternative delivery formats, continue to lower treatment burden and expand therapeutic choice.

Payer engagement has matured from transactional reimbursement to an emphasis on outcomes and total cost of care, creating incentives for manufacturers to prove real-world effectiveness and patient-reported outcomes. Meanwhile, care delivery is decentralizing as home-based infusion, remote monitoring, and specialized community clinics become more capable of supporting complex regimens. Technological enablers-from digital adherence tools to remote factor-level monitoring-are reducing barriers to individualized care while generating new types of evidence. Together, these forces are creating a landscape in which strategic agility, robust evidence generation, and patient-centered services determine which innovations achieve widespread clinical adoption and sustained commercial viability.

Practical implications of evolving tariff policies on procurement, logistics, and contractual structures that affect access continuity and commercial stability in hemophilia treatments

In 2025, adjustments to tariff frameworks and cross-border trade policies have created material considerations for procurement strategies, supply chain resilience, and pricing negotiations across therapeutic categories. Manufactures and distributors are reassessing sourcing footprints and logistics to mitigate potential cost pass-throughs that can affect affordability for both health systems and patients. In response, many stakeholders are prioritizing supply chain visibility and contractual flexibility to manage intermittent cost fluctuations and customs-related delays.

Procurement teams are increasingly favoring diversified supplier networks and nearshoring options to reduce exposure to tariff volatility. Concurrently, contracting strategies are shifting toward longer-term agreements with defined service levels and contingency clauses to preserve continuity of care. These changes are also prompting manufacturers to reconsider geographic launch sequencing and to refine value communication to payers and health systems where tariff-induced cost pressures are most pronounced. Ultimately, the cumulative impact of tariff changes emphasizes the need for integrated commercial and operational planning to protect patient access while maintaining commercial sustainability.

Comprehensive segmentation insights connecting therapeutic modalities, treatment modes, care settings, and distribution pathways to reveal differentiated value creation opportunities

Segment-focused insights reveal where clinical needs, care settings, and delivery channels intersect to influence adoption pathways and service design. When studying the therapeutic class dimension, the contrast between gene therapy and replacement therapy clarifies divergent development priorities: gene-based approaches require long-term safety surveillance, specialized manufacturing, and outcomes demonstration, whereas replacement therapies concentrate on dosing convenience, supply chain reliability, and incremental clinical differentiation. From the treatment mode perspective, the distinction between on-demand treatments and prophylaxis illuminates differing patient engagement models and resource utilization; prophylactic regimens center on preventing bleeding episodes and supporting continuous adherence programs, while on-demand approaches emphasize rapid access, acute care coordination, and emergency readiness.

Consideration of end user profiles-home healthcare, hospitals, and specialized clinics-shows how care setting influences service requirements and commercial outreach. Home healthcare models demand decentralized distribution, caregiver education, and remote monitoring solutions, whereas hospital-centric care leans on institutional formularies, inpatient logistics, and acute care integration. Specialized clinics act as hubs for complex case management, multidisciplinary coordination, and registry-driven evidence collection. Finally, distribution channel analysis across hospital pharmacy and retail pharmacy underscores different procurement pathways and patient touchpoints; hospital pharmacies often handle institutional contracting and inpatient support, while retail pharmacies influence outpatient adherence, accessibility, and community-level patient education. By integrating therapeutic class, treatment mode, end user, and distribution channel perspectives, stakeholders can identify tailored value propositions and aligned service models for distinct patient cohorts.

How regional regulatory, reimbursement, and care delivery variations across major global regions translate into differentiated access dynamics and commercial approaches

Regional dynamics shape regulatory expectations, care delivery norms, and payer frameworks in ways that directly affect clinical adoption and commercial strategy. In the Americas, innovation adoption is often accompanied by intense payer scrutiny and sophisticated outcomes-based contracting pilots; public and private payers demand comprehensive evidence packages and real-world data to justify higher-cost interventions, while patient advocacy groups influence access pathways and policy priorities. Policy variation across states and provinces adds another layer of complexity that requires localized engagement strategies.

Across Europe, Middle East & Africa, diverse regulatory architectures and reimbursement pathways necessitate bespoke market approaches. Some countries emphasize centralized health technology assessment and value demonstration, while others maintain decentralized procurement mechanisms that prioritize cost containment and formulary management. Access in lower-resource settings often hinges on tiered pricing models and partnerships with non-governmental organizations. In the Asia-Pacific region, a mix of rapidly modernizing healthcare systems and large public payers creates both opportunity and constraint. Regulatory agility in certain jurisdictions can accelerate approvals for novel therapies, but reimbursement timelines and budget impact assessments remain critical determinants of uptake. Collectively, these regional characteristics underline the importance of aligning clinical evidence generation, pricing strategy, and stakeholder engagement with local regulatory and payer expectations.

Critical organizational capabilities, partnership models, and evidence strategies that distinguish successful companies in the evolving hemophilia treatment landscape

Company-level dynamics distinguish organizations that achieve clinical traction and sustainable access from those that face roadblocks. Strategic leadership, manufacturing scale, and robust evidence-generation capabilities enable advanced therapy pioneers and established biologics manufacturers to navigate complex regulatory landscapes and secure reimbursement dialogues. Firms that invest in distributed manufacturing capacity, cold-chain logistics, and specialized training programs for treating centers can materially reduce launch friction and support continuity of care.

Partnership models are also critical: collaborations between developers, specialty pharmacies, payers, and provider networks facilitate integrated pathways for patient identification, initiation of therapy, and long-term monitoring. Technology integration-such as digital adherence platforms, telehealth-enabled follow-up, and centralized registries-amplifies the value proposition by producing real-world outcomes and improving patient retention. Conversely, companies that under-invest in post-market evidence and stakeholder engagement often encounter payer pushback and slower clinical adoption. In sum, the most successful organizations demonstrate an ability to combine scientific differentiation with operational excellence, strong stakeholder relationships, and an evidence strategy that speaks to clinical, economic, and patient-centered endpoints.

Actionable strategic priorities for leadership teams to align evidence generation, supply resilience, payer engagement, and patient-centered services for sustained impact

Industry leaders should pursue a set of prioritized actions that align clinical innovation with payer expectations, operational resilience, and patient-centered design. First, embed robust real-world evidence generation into development plans to anticipate payer needs and support outcomes-based contracting. By integrating registries, remote monitoring, and patient-reported outcomes into post-approval programs, organizations can demonstrate sustained clinical benefits and inform value propositions. Second, invest in supply chain flexibility and regional logistics to mitigate tariff-related disruptions and ensure uninterrupted patient access; nearshoring, diversified suppliers, and contingency agreements with distributors can preserve continuity.

Third, develop bespoke launch playbooks that reflect local regulatory and reimbursement nuances: engage early with health technology assessment bodies, tailor economic models to reflect real-world care pathways, and prepare targeted materials for clinical and payer audiences. Fourth, strengthen patient support infrastructures that facilitate home-based care, adherence, and psychosocial support; comprehensive patient services increase persistence and optimize clinical outcomes. Finally, cultivate payer and provider partnerships that explore innovative contracting approaches, risk-sharing arrangements, and integrated care pathways. These combined actions will accelerate responsible adoption of advanced therapies while protecting patient access and demonstrating sustainable value.

A transparent, mixed-methods research design combining expert primary interviews and systematic secondary analysis to deliver reproducible, stakeholder-informed insights

The research approach combined structured primary engagement with systematic secondary synthesis to ensure balanced perspectives and credible conclusions. Primary inputs included in-depth interviews with clinical experts, payers, supply chain professionals, and patient advocacy representatives to capture operational realities, reimbursement considerations, and lived experience. These conversations informed the development of hypothesis-driven inquiry and guided targeted follow-up to validate emerging themes. Secondary review encompassed peer-reviewed literature, regulatory guidance, clinical trial reports, and public policy documents to anchor interpretations in current scientific and regulatory contexts.

Data triangulation was used to reconcile disparate inputs and to highlight convergent insights across stakeholders. The methodology included qualitative coding to identify recurrent themes and scenario-based analysis to explore plausible operational responses to policy and market shifts. Where appropriate, methodological limitations and boundary conditions were identified, including areas requiring ongoing evidence accumulation such as long-term safety and real-world effectiveness for novel modalities. Transparency about data sources, interview respondent profiles, and analytic assumptions supports reproducibility and helps users apply the findings within their own strategic frameworks.

A concise synthesis emphasizing cross-stakeholder collaboration, evidence alignment, and operational agility as the decisive factors for translating innovation into patient access

The hemophilia treatment environment is at an inflection point where scientific progress, payer scrutiny, and operational imperatives converge. Durable therapeutic innovations create the promise of reduced treatment burden and improved patient outcomes, yet realizing that promise depends on intentional evidence strategies, resilient supply chains, and finely tuned market engagement. Stakeholders that proactively align clinical development with payer requirements, invest in patient support and monitoring infrastructures, and adapt distribution strategies to regional realities will be best positioned to convert innovation into accessible care.

Sustained progress will require collaboration across manufacturers, providers, payers, and patient communities to co-create pathways that balance clinical benefit with affordability and equitable access. Continued monitoring of regulatory and policy shifts, investment in real-world evidence, and agility in operational execution are essential. In the face of complexity, strategic clarity and cross-functional coordination will determine which therapies achieve meaningful, scalable impact for people living with hemophilia.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hemophilia Treatment Market, by Therapeutic Class

  • 8.1. Gene Therapy
  • 8.2. Replacement Therapy

9. Hemophilia Treatment Market, by Treatment Mode

  • 9.1. On-Demand
  • 9.2. Prophylaxis

10. Hemophilia Treatment Market, by End User

  • 10.1. Home Healthcare
  • 10.2. Hospitals
  • 10.3. Specialized Clinics

11. Hemophilia Treatment Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Hemophilia Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Hemophilia Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Hemophilia Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Hemophilia Treatment Market

16. China Hemophilia Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alnylam Pharmaceuticals, Inc.
  • 17.6. Bayer AG
  • 17.7. BioMarin Pharmaceutical Inc.
  • 17.8. Centessa Pharmaceuticals plc
  • 17.9. CSL Behring LLC
  • 17.10. Expression Therapeutics LLC
  • 17.11. F. Hoffmann-La Roche Ltd
  • 17.12. Freeline Therapeutics Holdings plc
  • 17.13. GC Biopharma Corp.
  • 17.14. Grifols, S.A.
  • 17.15. Kedrion Biopharma Inc.
  • 17.16. Novo Nordisk A/S
  • 17.17. Octapharma AG
  • 17.18. Pfizer Inc.
  • 17.19. Sangamo Therapeutics, Inc.
  • 17.20. Sanofi S.A.
  • 17.21. Spark Therapeutics, Inc.
  • 17.22. Swedish Orphan Biovitrum AB (publ)
  • 17.23. Takeda Pharmaceutical Company Limited
  • 17.24. uniQure N.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HEMOPHILIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REPLACEMENT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REPLACEMENT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REPLACEMENT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ON-DEMAND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ON-DEMAND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ON-DEMAND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 35. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 36. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 39. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 41. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 46. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 50. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 61. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 66. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 77. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 82. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 83. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. GCC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 98. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. G7 HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 103. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. NATO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. CHINA HEMOPHILIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)